Renal Involvement in Patients with Vasculitis: Update in Diagnosis and Management

Essay

Submitted for partial fulfillment of Master Degree in Internal Medicine

By
Walaa Attia El Sayed Sheba
M.B.B.ch.
Faculty of Medicine - Alexandria University

Under Supervision of

Prof. / Dahlia Abdel-Mohsen Hussein

Professor of Internal Medicine & Rheumatology Faculty of medicine - Ain Shams University

Dr. / Hanan Mohammed Farouk

Assistant Professor of Internal Medicine & Rheumatology Faculty of medicine - Ain Shams University

Dr. / Sameh Abdel-Moteleb Hassan

Lecturer of Internal Medicine & Rheumatology Faculty of medicine - Ain Shams University

> Faculty of Medicine Ain Shams University 2010

List of figures

Figure	Title	Page
Figure.1	Classification of vasculitides in adult.	10
Figure.2	Clinical manifestation of Kawasaki disease	26
Figure.3	Leucocytoclastic vasculitis	33
Figure.4	Cutaneous ulceration on the elbow of a patient with the Churg_ Strauss syndrome	54
Figure.5	Petechiae in Henoch-Schönlien Purpura	74
Figure.6	Palpable Purpura	88
Figure.7	Necrotizing glomerulonephritis	96
Figure.8	Immunofluorescence microscopy demonstrating large, globular mesangial IgA deposits that are diagnostic of IgA nephropathy or Henoch-Schönlein purpura	98

List of Tables

Table	Title	Page
1	Classification of systemic vasculitis	9
2	Drugs alleged to cause hypersensitivity vasculitis	66
3	Vasculitis accompanying connective tissue disease	84
4	Infection-Associated Vasculitis	85
5	Neoplasia-Associated Vasculitis.	86

تأثر الكلى في مرض التهاب الاوعية الدموية:

التشخيص والجديد في العلاج

بحث مقدم لكليه الطب جامعة عين شمس إيفاءا جزئيا لشروط الحصول على درجه الماجستير في الأمراض الباطنة

مقسدم من

ولاء عطيه السيد شيبه

بكالوريوس الطب والجراحة كلية الطب - جامعة الأسكندريه

المشرفون

الأستاذ الدكتور/داليا عبد المحسن حسين

أستاذ الأمراض الباطنة والأمراض الروماتيزمية كلية الطب - جامعة عين شمس

دكتور/حنان محمد فاروق

أستاذ مساعد الأمراض الباطنة والأمراض الروماتيزمية كلية الطب - جامعة عين شمس

دكتور/سامح عبد المطلب حسن

مدرس الباطنة العامة والأمراض الروماتيزمية كلية الطب - جامعة عين شمس

كلية الطب- جامعة عين شمس **2010**



First of all, thanks to **ALLAH** to whom I relate any success in achieving any work in my life.


I would like to express my sincere gratitude to **Prof. Dr. Dahlia Abdel-Mohssein Hussein**, Professor of Internal Medicine & Rheumatology, Faculty of Medicine, Ain Shams University for allowing me to work under her supervision and for her encouragement and helpful advice. She had expressed so much sincere care and devoted much.


My deepest appreciation and profound gratitude to **Dr.** *Hanan Mohamed Farouk* Assistant professor of Internal Medicine & Rheumatology, Faculty of Medicine, Ain Shams University, for her kind supervision, encouragement and constant help. She had really offered me much of her time and experience.

I am very grateful to **Dr.** *Sameh Abdel-Moteleb Hassan*, Lecturer of Internal Medicine & Rheumatology, Faculty of Medicine, Ain Shams University, for his guidance, precious advice and continuous support, in every step in this work.

There is no word can be said to my family, Thank you will be much less than you deserve.

Walaa Attia.







بسم الله الرحمن الرحيم

﴿رَبِحٌ أَوْرِغُنِي أَنْ أَهُكُرَ نِعُمَتَكَ الَّتِي أَنْعَهُ الْعَهُ عَلَى الْعَهُ الْعَهُ عَلَى الْعَهُ الْح عَلَيَّ وَعَلَى وَالِدَيِّ وَأَنْ أَعْمَلَ حَالِمًا تَرْخَاهُ وَأَخْلِحُ لِي فِي ذُرِيِّتِي إِنِّي تُنْبِعُ إِلَيْكَ وَإِنِّي مِنَ الْمُسْلِمِينَ ﴾

حدق الله العظيم

سورة الأحقاف الآية (١٥)





List of Abbreviations		
AAVs	ANCA associated vasculitis	
	Randomized trial of Abatacept for systemic	
ABAVAS	vasculitis	
Abs	Antibodies	
ACR	American College of Rheumatology	
ANA	Antinuclear Antibody	
ANCA	Antineutrophil cytoplasmic antibodies	
Anti-GBM	Anti-glomerular basement membrane antibodies	
APRIL	A proliferation –inducing ligand	
ASVV	ANCA associated small vessel vasculitis	
ATG	Antimocyte globulin	
ATN	Acute tubular necrosis	
BLYS	B-lymphocyte simulater	
BVAS	Birmingham Vasculitis Activity Score	
C3	Complement 3	
C4	Complement 4	
C5	Complement 5	
C-ANCA	Cytoplasmic antineutrophil cytoplasmic antibody	
CD 4	Cluster Differentiation 4	
CD20	Cluster Differentiation 20	
CD 28	Cluster Differentiation 28	
CD 52	Cluster Differentiation 52	
CSS	Churg Strauss Syndrome	
	Prospective randomized control trial of	
CYCAZAREM	Cyclophosphamide and azathioprine remission	
CYCLOPS	Trial of pulsed versus oral cyclophosphamide	
DAH	Diffuse alveolar hemorrhage	
DHFR	Dihydrofolate reductase	
ELISA	Enzyme linked immunosorbent assay	
ESR	Erythrocyte sedimentation rate	

EULAR	European League Against Rheumatism	
EUVAS	European Vasculitis Study Group	
FH2	Dihydrofolic acid	
Fc	Crystalline fragment	
GCA	Giant cell arteritis	
GFR	Glomerular filtration rate	
GIT	Gastrointestinal tract	
HBV	Hepatitis B virus	
HCV	Hepatitis C virus	
HHV	Human Herpes virus	
HIV	Human immundeficiency virus	
HLA	Human leucocyte antigen	
HSP	Henoch-Schölein Purpura	
IFN-gama	Interferon-gama	
IgA	Immunoglobulin A	
IgE	Immunoglobulin E	
IgG	Immunoglobulin G	
IgM	Immunoglobulin M	
IL	Interleukin	
IMPROVE trial	Mycophenolate mofetil versus azathioprine trial	
IVIG	Intravenous immunoglobulin	
KD	Kawasaki disease	
LTMAs	Leukotriene modifying agents	
	MAINtenance of remission using RITuximab in	
MAINRITSAN	Systemic ANCA associated vasculitis trial	
MCP1	Monocyte chemoattractant protein 1	
MGCs	Multinucleated giant cells	
MPGN	Membranoproliferative glomerulonephritis	
MMF	Mycophenolate mefetil	
MMP2	Matrix metalloproteinases	
MPA	Microscopic polyangitis	
MPO	Myloperoxidase	
MTX	Methotrexate	
MYCYC	Mycophenolate and cyclophosphamide trial	

NIH	National Institute of Health	
NPV	Negative predictive value	
PAN	Polyarteritis nodosa	
p-ANCA	Perinuclear antineutrophil cytoplasmic antibody	
PCP	Pneumocystis carinii pneuomonia	
PDGF	Platelet derived growth factor	
PE	Plasma exchange	
PMR	Polymyalgia rheumatic	
PPV	Positive predictive value	
PR3	Proteinase 3	
PSS	Primary Systemic Sclerosis	
RA	Rheumatiod arthritis	
RCT	Randomized controlled trial	
RF	Rheumatoid factor	
	Randomized trial of Rituximab versus	
RITUXVAS	cyclophosphamide for renal vasculitis	
RPGN	Rapidly progressive glomerulonephritis	
SLE	Systemic Lupus Erythematosus	
S cr	Serum creatinine	
SS	Sjogren's syndrome	
SYK	Spleen tyrosine kinase	
	Transmembrane activator and calcium modulator	
TACI	and cyclophilin ligand interactor	
TGF-beta	Transforming growth factor-beta	
Th 17	T- helper 17 cells	
TIMP	Tissue inhibitor of MMP	
TNF-α	Tumor necrosis factor-alpha	
TTP	Thrombotic thrombocytopenic purpura	
UCTD	Unclassified Connective Tissue Disease	
VEGF	Vascular endothelial growth factor	
WBC	White blood cell count	
WG	Wegener's granulomatosis	

LIST OF CONTENTS

Title	Page No.
List of abbraviations	
List of abbreviations	1
Content	<u>i</u> v
List of Figures	v
List of Tables	vi
Introduction	1
Aim of the work	6
Review of Literature	
- Systemic Vasculitis and renal involvement	in patients
with vasculitis	7
- Update in diagnosis and management of rer	ıal
vasculitis	92
Summary	133
References	135
Arabic Summary	

INTRODUCTION

Vasculitis is inflammation of blood vessels with demonstrable structural injury of the vessel wall. The clinical and pathological features are variable and depend on the type and the size of the involved blood vessels and the tissue and organ damage caused by vascular occlusion (Saleh and John, 2005).

The main types of vasculitides can be described using clinical features and pathological findings according to the Chapel Hill Classification (1994) into: Large vessel vasculitis (Giant Cell arteritis, Takayasu's arteritis) Medium vessel vasculitis (Polyarteritis Nodosa, Kawasaki's disease) Small vessel vasculitis (ANCA associated including Wegener's granulomatosis, Churg Strauss syndrome, Microscopic polyangitis and ANCA unassotiated including Henoch-Schönlein purpura, Essential cryoglobulinemic vasculitis and cutaneous leukocytoclastic angitis) (Saleh and John, 2005).

Vasculitides affecting the kidneys are typically associated with hematuria and proteinuria, frequently presenting as a rapidly progressive necrotizing glomerulonephritis (Pauci-immune necrotizing glomerulonephritis). Glomerular injury occurs in the setting of the small vasculitis, associated with antineutrophil cytoplasmic vessel autoantibodies (ANCA), antiglomerular basement membrane antibodies (anti-GBM), or the presence of immune complex formation such as with Henoch-Schönlein Purpura (HSP), cryoglobulinemic vasculitis, and systemic lupus erythematosus (SLE) (Walters et al., 2010).

Pauci-immune necrotizing glomerulonephritis is a somewhat confusing term. Pauci originates from the Latin word paucus meaning little or few. It reflects the almost complete absence of immunoglobulin deposits (as assessed by immunofluorescence) when studying renal biopsies of a subgroup of patients with rapidly progressive glomerulonephritis (*Rutgers et al.*, 2010).

Historically, pauci-immune glomerulonephritis has been described as a form of glomerulonephritis with no evidence of linear immunoglobulin deposition (type I glomerulonephritis, as in Goodpasture disease) or immune complex deposition (type II glomerulonephritis, as in lupus nephritis). However, paucity of immune deposits does not imply that the immune system is not involved in the disease process; on the contrary, pauci-immune renal disease is believed to be a typical immune-mediated disease and is treated accordingly (*Jabur and Saeed*, *2010*).

Why is the disease sometimes limited to the kidneys?

This issue has no definite answer. Two types of reasoning exist. First, the disease process itself might specifically target a particular, organ-specific vasculature. Second, the unique characteristics of certain types of vasculature could make them vulnerable to an immunologically mediated attack (*Flint et al.*, 2010).

The unique characteristics could be intrinsically present but not previously recognized by the immune system (eg, the noncollagenous domain of type IV collagen in Goodpasture disease), or could be acquired

by the vasculature either by deposition of antigen (eg, in situ formation of immune complexes in poststreptococcal glomerulonephritis), change of a preexisting antigen (formation of neoepitopes), or change in endothelial function (*Ball*, 2010).

Essential to the pathogenesis of pauci-immune renal disease is inflammation of blood vessels. The endothelium plays a crucial role in this process. Thus, organ-specific endothelial antibodies could explain organ-specific disease manifestations, although the presence of these antibodies in most patients was not confirmed (*Bollee et al.*, 2009).

The glomerulus has a unique type of fenestrated endothelium allowing for filtration of blood and the production of urine. The fenestrae are covered by a highly negatively charged glycocalyx, which is in part responsible for the glomerular filtration barrier. These characteristics could facilitate capturing of ANCA antigens (especially the highly positively charged myeloperoxidase) resulting in local inflammation in the presence of ANCA (*Rihova*, 2009).

Also, local cytokine production in the kidney could induce on-site neutrophil priming, a necessary step for ANCA-induced neutrophil activation and endothelial damage. The unique microvasculature in the glomerulus could allow local trapping of activated neutrophils and thus could be responsible for local inflammation. Likely a combination of local and systemic factors determines the location and severity of active vasculitis and its disease course (*Shaikh and Ansari*, 2009).

But renal involvement is more frequently part of a multiorgan disease that may affect the skin, upper and lower respiratory tracts, and the musculoskeletal, gastrointestinal, and nervous systems (*Galesic et al.*, 2009).

Renal involvement is common in any of the forms of systemic vasculitis. These include classic polyarteritis nodosa, Wegener's granulomatosis, microscopic polyarteritis, Churg-Strauss syndrome, and the hypersensitivity vasculitides (including Henoch-Schönlein purpura, mixed cryoglobulinemia, and serum sickness) (*Walters et al., 2008*).

In Polyarteritis nodosa (PAN) the kidneys are the most commonly involved organ. Renal involvement frequently leads to variable degrees of renal insufficiency and hypertension. In addition, rupture of renal arterial aneurysms can cause perirenal hematomas. Multiple renal infarctions may also develop in those with severe vasculitis. Incomplete luminal narrowing of the inflamed arteries leads to glomerular ischemia but not inflammation or necrosis (*Unverdi et al.*, 2009).

In Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) renal biopsy reveals a segmental necrotizing glomerulonephritis with few or no immune deposits (pauci-immune) on immunofluorescence and electron microscopy. The glomerular involvement is often accompanied by mononuclear tubulointerstitial infiltrates. However, occasional patients present with an interstitial nephritis with or without granuloma formation in the absence of the typical glomerular lesions.

Such patients may subsequently develop the classic pauci-immune necrotizing glomerulonephritis (*Chen et al.*, 2007).

In The Churg-Strauss syndrome (CSS) kidney affection may be more common than is generally reported. On renal biopsy, focal segmental glomerulonephritis is the predominant lesion, and is often associated with necrotizing features and crescents (*Keogh and Specks*, 2006).

In hypersensitivity vasculitis, the term "hypersensitivity vasculitis" refers to a vasculitis of small blood vessels of the skin (especially arterioles and venules), which is secondary to an immune response or hypersensitivity reaction to an exogenous substance. The nomenclature of hypersensitivity vasculitis is diverse and often confusing. Names often used interchangeably but inappropriately have included drug-induced vasculitis, leukocytoclastic vasculitis, cutaneous vasculitis, serum sickness or serum sickness-like reactions and allergic vasculitis. Serum sickness and serum sickness-like reactions may, but in many cases do not, have a vasculitic component. Renal involvement is usually mild (Jennett and Falk, 2004).

Vasculitis may also occur as a secondary feature in other diseases, such as (infection related vasculitis as HCV infection, connective tissue disease as RA &SLE, malignancy related vasculitis as lymphoma & leukemia, drug hypersensitivity related vasculitis and post organ transplant vasculitis) (*Luqmanic and Pathare*, 2005).